Eli Lilly to Acquire Verve Therapeutics for ~$1.3B
Shots:
- Eli Lilly has entered into a definitive agreement to acquire Verve Therapeutics to advance cardiovascular therapies
- As per the deal, Lilly will acquire Verve for $10.50/share in an all-cash transaction totaling ~$1B, along with one non-tradeable CVR of $3/share tied to first pts dosing with VERVE-102 for ASCVD in P-III trial by year 10 post-closing; closing expected in Q3’25, with a second-step merger for untendered shares
- VERVE-102, an in vivo gene editing therapy targeting PCSK9, is being evaluated in a P-Ib trial for ASCVD & has received FTD from the US FDA
Ref: Eli Lilly | Image: Verve Therapeutics | Press Release
Related News:- Sanofi to Acquire Blueprint Medicines for ~$9.5B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com